Drug Resistance in Targeted Cancer Therapies with RAF Inhibitors

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582307

Authors

Ufuk Degirmenci

Jiajun Yap

Yuen Rong M Sim

Shiru Qin

Jiancheng Hu

Affiliations

Soon will be listed here.

Abstract

Hyperactive RAS/RAF/MEK/ERK signaling has a well-defined role in cancer biology. Targeting this pathway results in complete or partial regression of most cancers. In recent years, cancer genomic studies have revealed that genetic alterations that aberrantly activate the RAS/RAF/MEK/ERK signaling mainly occur on RAF or upstream, which motivated the extensive development of RAF inhibitors for cancer therapy. Currently, the first-generation RAF inhibitors have been approved for treating late-stage cancers with BRAF(V600E) mutations. Although these inhibitors have achieved promising outcomes in clinical treatments, their efficacy is abolished by quick-rising drug resistance. Moreover, cancers with hyperactive RAS exhibit intrinsic resistance to these drugs. To resolve these problems, the second-generation RAF inhibitors have been designed and are undergoing clinical evaluations. Here, we summarize the recent findings from mechanistic studies on RAF inhibitor resistance and discuss the critical issues in the development of next-generation RAF inhibitors with better therapeutic index, which may provide insights for improving targeted cancer therapy with RAF inhibitors.

Citing Articles

Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers.

Biersack B, Nitzsche B, Hopfner M Cancer Drug Resist. 2025; 8:6.

PMID: 39935431 PMC: 11810460. DOI: 10.20517/cdr.2024.125.

Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold.

Wan X, Yap J, Chen J, Li Y, Faruk R, Tan N Theranostics. 2025; 15(5):2035-2051.

PMID: 39897565 PMC: 11780520. DOI: 10.7150/thno.103958.

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.

The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma.

Malamos P, Papanikolaou C, Gavriatopoulou M, Dimopoulos M, Terpos E, Souliotis V Int J Mol Sci. 2024; 25(13).

PMID: 39000097 PMC: 11241508. DOI: 10.3390/ijms25136991.

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y Signal Transduct Target Ther. 2024; 9(1):132.

PMID: 38763973 PMC: 11102923. DOI: 10.1038/s41392-024-01823-2.

References

Gibney G, Messina J, Fedorenko I, Sondak V, Smalley K . Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013; 10(7):390-9. PMC: 3983565. DOI: 10.1038/nrclinonc.2013.83. View

Leicht D, Balan V, Zhu J, Kaplun A, Bronisz A, Rana A . MEK-1 activates C-Raf through a Ras-independent mechanism. Biochim Biophys Acta. 2013; 1833(5):976-86. PMC: 3608709. DOI: 10.1016/j.bbamcr.2013.01.015. View

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S . Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014; 25(5):697-710. PMC: 4049532. DOI: 10.1016/j.ccr.2014.03.011. View

Lin W, Iversen L, Tu H, Rhodes C, Christensen S, Iwig J . H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc Natl Acad Sci U S A. 2014; 111(8):2996-3001. PMC: 3939930. DOI: 10.1073/pnas.1321155111. View

Dhillon A, Yip Y, Grindlay G, Pakay J, Dangers M, Hillmann M . The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal. 2009; 21(11):1645-51. DOI: 10.1016/j.cellsig.2009.07.001. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

Arora A, Scholar E . Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315(3):971-9. DOI: 10.1124/jpet.105.084145. View

Pahuja K, Nguyen T, Jaiswal B, Prabhash K, Thaker T, Senger K . Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell. 2018; 34(5):792-806.e5. PMC: 6248889. DOI: 10.1016/j.ccell.2018.09.010. View

Yuan J, Dong X, Yap J, Hu J . The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020; 13(1):113. PMC: 7433213. DOI: 10.1186/s13045-020-00949-4. View

10.

Van Aelst L, Barr M, MARCUS S, Polverino A, Wigler M . Complex formation between RAS and RAF and other protein kinases. Proc Natl Acad Sci U S A. 1993; 90(13):6213-7. PMC: 46898. DOI: 10.1073/pnas.90.13.6213. View

11.

Taylor S, Shaw A, Hu J, Meharena H, Kornev A . Pseudokinases from a structural perspective. Biochem Soc Trans. 2013; 41(4):981-6. PMC: 4399968. DOI: 10.1042/BST20130120. View

12.

Liau N, Wendorff T, Quinn J, Steffek M, Phung W, Liu P . Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Nat Struct Mol Biol. 2020; 27(2):134-141. DOI: 10.1038/s41594-019-0365-0. View

13.

Lavoie H, Therrien M . Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015; 16(5):281-98. DOI: 10.1038/nrm3979. View

14.

Jura N, Endres N, Engel K, Deindl S, Das R, Lamers M . Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009; 137(7):1293-307. PMC: 2814540. DOI: 10.1016/j.cell.2009.04.025. View

15.

Ambrosio L, Mahowald A, Perrimon N . Requirement of the Drosophila raf homologue for torso function. Nature. 1989; 342(6247):288-91. DOI: 10.1038/342288a0. View

16.

Yuan J, Ng W, Yap J, Chia B, Huang X, Wang M . The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF. J Biol Chem. 2018; 293(37):14276-14284. PMC: 6139560. DOI: 10.1074/jbc.RA118.004597. View

17.

Zhang X, Settleman J, Kyriakis J, Elledge S, Marshall M, Bruder J . Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature. 1993; 364(6435):308-13. DOI: 10.1038/364308a0. View

18.

Han M, Golden A, Han Y, Sternberg P . C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation. Nature. 1993; 363(6425):133-40. DOI: 10.1038/363133a0. View

19.

Zaman A, Wu W, Bivona T . Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019; 11(8). PMC: 6721448. DOI: 10.3390/cancers11081197. View

20.

Dawson J, Berger M, Lin C, Schlessinger J, Lemmon M, Ferguson K . Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol. 2005; 25(17):7734-42. PMC: 1190273. DOI: 10.1128/MCB.25.17.7734-7742.2005. View